RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  2009-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijrobp.2008.08.002PMID 18947938PMCID PMC2905150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

  2009influential reference
• Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

  2008cited by this paper
• Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.

  2008cited by this paper
• Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

  2008cited by this paper
• Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.

  2007cited by this paper
• Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.

  2007cited by this paper
• 22: Ten Year Follow-up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

  2006cited by this paper
• Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

  2006cited by this paper
• Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

  2005influential reference
• Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy.

  2005cited by this paper
• Focal therapy in prostate cancer: future trends

  2005cited by this paper
• Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer.

  2004cited by this paper
• Validity of sentinel lymph node concept for patients with prostate cancer.

  2004cited by this paper
• Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy.

  2004cited by this paper
• Is a limited lymph node dissection an adequate staging procedure for prostate cancer?

  2002cited by this paper
• Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.

  2002cited by this paper
• Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

  2002cited by this paper
• The Sentinel Lymph Node Concept in Prostate Cancer – First Results of Gamma Probe-Guided Sentinel Lymph Node Identification

  1999cited by this paper
• ATLAS OF HUMAN ANATOMY (2ND ED.)

  1999cited by this paper
• Prostate cancer: anatomical and surgical considerations.

  1996influential reference
• Extended pelvic lymphadenectomy for prostatic cancer.

  1980cited by this paper
• Extended pelvic lymphadenectomy for prostatic cancer.

  1979cited by this paper
• Prostatic lymphography.

  1979cited by this paper
• An evaluation of lymphangiography in staging carcinoma of the prostate.

  1975cited by this paper
• Atlas of Human Anatomy

  1880cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Dosimetric Impact of Artificial Intelligence (AI)-Based Autocontouring Software, OncoStudio, in High-Risk Prostate Cancer Treatment Planning: A Three-Group Comparative Study on the Slice Ranges of Seminal Vesicles

  2026cites this paper
• Ultrahypofractionated Versus Conventionally Fractionated Whole-pelvis Radiotherapy in Prostate Cancer: A Randomized Clinical Trial.

  2026cites this paper
• Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study

  2026cites this paper
• Patient- and clinician-reported acute radiation-induced diarrhoea in patients with prostate cancer during curative external radiation therapy: A prospective observational cohort study

  2025cites this paper
• Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium.

  2025cites this paper
• Quality Assessment of Commercial Contouring Software based on Convolutional Neural Networks: Implications for Clinical Practice

  2025cites this paper
• Medical imaging and artificial intelligence in radiotherapy of malignant tumors

  2025cites this paper
• PSMA PET‐directed radiotherapy for prostate cancer: From precision planning to future innovations

  2025cites this paper
• PSMA-PET/CT-based salvage elective nodal radiotherapy for lymph node recurrence following radical prostatectomy

  2025cites this paper
• Online Adaptive Radiotherapy for Bladder Preservation: Transitioning to Hypofractionation.

  2025cites this paper
• Extended field chemoradiation in M1a bladder carcinoma: A case report.

  2025cites this paper
• Incidence and predictors of lower extremity lymphedema after postoperative radiotherapy for prostate cancer

  2025cites this paper
• Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.

  2025cites this paper
• Dosimetric Comparison of Organs At Risk Between Artificial Intelligence-Based Auto-Contouring and Manual Contouring for High-Risk Prostate Cancer Radiotherapy: A Retrospective Study

  2025cites this paper
• Volumetric Changes and Acute Toxicity with 68Ga Prostate-Specific Membrane Antigen vs 18F-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial.

  2025cites this paper
• Bowel bag dosimetric parameters for ultrahypofractionated pelvic elective nodal irradiation in prostate cancer.

  2025cites this paper
• Stereotactic Radiotherapy to the Prostate and Pelvic Lymph Nodes for High-Risk and Very High-Risk Prostate Cancer in a Setting with a Hydrogel Spacer: A Toxicity Report

  2025cites this paper
• Factors associated with mesorectal lymph node metastasis in prostate cancer patients

  2025cites this paper
• Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30).

  2025cites this paper
• Volumetric Modulated Arc Therapy for High-Risk and Very High-Risk Locoregional Prostate Cancer in the Modern Era: Real-World Experience from an Asian Cohort

  2024cites this paper
• Androgen deprivation alone versus combined with pelvic radiation for adverse events and quality of life in clinically node-positive prostate cancer

  2024cites this paper
• Lymph node oligometastases from prostate cancer: extensive or localized treatments - do we have a basis to decide?

  2024cites this paper
• Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer

  2024cites this paper
• Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials

  2024cites this paper
• Adaptive ultra‐hypofractionated whole‐pelvic radiotherapy in high‐risk and very high‐risk prostate cancer on 1.5‐Tesla MR‐Linac: Estimated delivered dose and early toxicity results

  2024cites this paper
• Patterns of Failure After Prostate-Only Radiotherapy in High-Risk Prostate Cancer: Implications for Refining Pelvic Nodal Contouring Guidelines.

  2024cites this paper
• Hypofractionated radiation therapy combined with androgen deprivation therapy for clinically node-positive prostate cancer

  2024cites this paper
• Hypofractionated radiation therapy combined with androgen deprivation therapy for high‐risk localized prostate cancer

  2024cites this paper
• Image-Guided Stereotactic Body Radiotherapy on Detectable Prostate Bed Recurrence after Prostatectomy in RT-Naïve Patients

  2024cites this paper
• Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer.

  2024cites this paper
• Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy

  2024cites this paper
• Post‐Prostatectomy Magnetic Resonance‐Guided Radiotherapy on a 1.5 Tesla Magnetic Resonance Integrated Linear Accelerator: Feasibility, Toxicity, and Preliminary Clinical Outcomes

  2024cites this paper
• Moderate hypofractionated radiotherapy to the prostate bed with or without pelvic lymph nodes: a prospective trial

  2024cites this paper
• Dose-escalated Salvage Whole-pelvic Radiotherapy for Biochemical Recurrence After Radical Prostatectomy for High-risk Prostate Cancer.

  2024cites this paper
• Hypofractionated Post-Prostatectomy Radiotherapy in 16 Fractions: A Single-Institution Outcome

  2023cites this paper
• Clinical evaluation of deep learning and atlas-based auto-segmentation for organs at risk delineation.

  2023cites this paper
• Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer

  2023cites this paper
• Updating approach for lexicographic optimization-based planning to improve cervical cancer plan quality

  2023influential citation
• Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial

  2023cites this paper
• A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer

  2023cites this paper
• Safety of ultra-hypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: Systematic Review and Meta-analysis.

  2023cites this paper
• Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study

  2023cites this paper
• Les grands principes des traitements du cancer de prostate localisé

  2023cites this paper
• Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study

  2023cites this paper
• Randomized trial of concomitant hypofractionated IMRT boost versus conventional fractionated IMRT boost for localized high-risk prostate cancer (pHART2-RCT).

  2023cites this paper
• Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-term Results from the PKUFH Randomized Phase III Trial.

  2023cites this paper
• CONSENSUS DELINEATION GUIDELINES FOR PELVIC LYMPH NODE RADIOTHERAPY OF PROSTATE CANCER: ON BEHALF OF THE FRANCOPHONE GROUP OF UROLOGICAL RADIATION THERAPY (GFRU).

  2023cites this paper
• Prostate‐specific membrane antigen positron emission tomography detected local failure after post‐prostatectomy radiation therapy: Low rates of out‐of‐field recurrence validates current Australian prostate bed contouring guidelines

  2023cites this paper
• Long-term outcomes of whole-pelvis radiation therapy using volumetric modulated arc therapy for high-risk prostate cancer

  2023cites this paper
• How smart is artificial intelligence in organs delineation? Testing a CE and FDA-approved Deep-Learning tool using multiple expert contours delineated on planning CT images

  2023cites this paper
• Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy

  2023cites this paper
• Is ultra-hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? Early results from the HOPE Trial.

  2023cites this paper
• Reduction of PTV margins for elective pelvic lymph nodes in online adaptive radiotherapy of prostate cancer patients

  2023cites this paper
• Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer

  2023cites this paper
• Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging

  2023cites this paper
• A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of Life

  2023cites this paper
• Long-term findings of rectal endoscopy and rectal bleeding after moderately hypofractionated, intensity-modulated radiotherapy for prostate cancer

  2023cites this paper
• Sentinel Node Procedure to Select Clinically Localized Prostate Cancer Patients with Occult Nodal Metastases for Whole Pelvis Radiotherapy

  2023cites this paper
• An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients

  2023cites this paper
• Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial

  2022cites this paper
• A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient‐reported quality of life

  2022cites this paper
• Common iliac node positive prostate cancer treated with curative radiotherapy: N1 or M1a?

  2022cites this paper
• Acute and late toxicity of prostate-only or pelvic SBRT in prostate cancer: A Comparative Study.

  2022cites this paper
• Long-term outcome of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate and high risk prostate cancer

  2022cites this paper
• The role of multiparametric mri in the diagnosis of local recurrence after radical prostatectomy and before salvage radiotherapy.

  2022cites this paper
• Long Term Results of Elective Nodal Salvage Radiotherapy in Oligometastatic Prostate Cancer : A Mono-Institutional Series

  2022cites this paper
• El papel de la resonancia magnética multiparamétrica en el diagnóstico de la recidiva local tras la prostatectomía radical y antes de la radioterapia de rescate

  2022cites this paper
• Oligorecurrent nodal prostate cancer: radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

  2022cites this paper
• Ocrtavanje organa od rizika u radioterapiji

  2022cites this paper
• Value of intermediate imaging in adaptive robust radiotherapy planning to manage radioresistance

  2022cites this paper
• Evaluation of an automated template-based treatment planning system for radiotherapy of anal, rectal and prostate cancer

  2022cites this paper
• The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

  2022cites this paper
• Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients

  2022cites this paper
• Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy

  2022cites this paper
• Late toxicity of moderately hypofractionated intensity-modulated proton therapy treating the prostate and pelvic lymph nodes for high-risk prostate cancer.

  2022cites this paper
• Comprehensive dosimetric and clinical evaluation of lexicographic optimization-based planning for cervical cancer

  2022cites this paper
• Dosimetric impact of rotational set-up errors in high-risk prostate cancer

  2022cites this paper
• Long-term outcome of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate and high risk prostate cancer

  2022cites this paper
• Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline.

  2022cites this paper
• Recent Applications of Artificial Intelligence in Radiotherapy: Where We Are and Beyond

  2022cites this paper
• VMAT partial arc technique decreases dose to organs at risk in whole pelvic radiotherapy for prostate cancer when compared to full arc VMAT and IMRT.

  2022cites this paper
• Urinary toxicity in patients treated with radical EBRT for prostate cancer: Analysis of predictive factors in an historical series.

  2022cites this paper
• Postoperative radiotherapy in prostate cancer: Dose and volumes.

  2021cites this paper
• Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study

  2021cites this paper
• The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy

  2021cites this paper
• Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.

  2021cites this paper
• Moderately Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-risk Localised Prostate Cancer: Predictors of Long-term Biochemical Control and Toxicity.

  2021cites this paper
• A rapid review of influential factors and appraised solutions on organ delineation uncertainties reduction in radiotherapy

  2021cites this paper
• The Role of Multiparametric Magnetic Resonance in Volumetric Modulated Arc Radiation Therapy Planning for Prostate Cancer Recurrence After Radical Prostatectomy: A Pilot Study

  2021cites this paper
• Dosimetric impact of physician style variations in contouring CTV for post-operative prostate cancer: A deep learning based simulation study

  2021cites this paper
• Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence

  2021cites this paper
• Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design

  2021cites this paper
• Comparison of helical tomotherapy with multi-field intensity-modulated radiotherapy treatment plans using simultaneous integrated boost in high-risk prostate cancer

  2021cites this paper
• Validating Modern NRG Oncology Pelvic Nodal and GFRU Prostate Bed Contouring Guidelines for Post-prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial.

  2021cites this paper
• Elective nodal ultra hypofractionated radiation for prostate cancer: safety and efficacy from four prospective clinical trials.

  2021cites this paper
• Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, toxicity and quality of life.

  2021cites this paper
• OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.

  2021cites this paper
• Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

  2021cites this paper
• Visualizing the urethra by magnetic resonance imaging without usage of a catheter for radiotherapy of prostate cancer

  2021cites this paper
• First experimental evaluation of multi-target multileaf collimator tracking during volumetric modulated arc therapy for locally advanced prostate cancer.

  2021cites this paper